Stockscreener 앱 받기
0.781
1.20%
-0.0095
시장 영업 전:
.78
-0.001
-0.13%
전일 마감가:
$0.7905
열려 있는:
$0.78
하루 거래량:
1.07M
Relative Volume:
0.42
시가총액:
$133.35M
수익:
$126.33M
순이익/손실:
$-82.68M
주가수익비율:
-1.3017
EPS:
-0.6
순현금흐름:
$-79.98M
1주 성능:
-8.80%
1개월 성능:
-13.85%
6개월 성능:
-22.67%
1년 성능:
-29.00%
1일 변동 폭
$0.78
$0.835
1주일 범위
$0.78
$0.8798
52주 변동 폭
$0.54
$1.53
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
0.781 | 133.35M | 126.33M | -82.68M | -79.98M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics expands board, appoints new director - Investing.com India
Check Out Seres Therapeutics Inc (MCRB)’s Trade Data Rather Than the Analysts’ Views - SETE News
Seres Therapeutics Expands Board with Nestlé’s Appointee - TipRanks
Recent Insider Activity Suggests Potential Gains for Seres Therapeutics Inc (MCRB) - Knox Daily
A year in review: Seres Therapeutics Inc (MCRB)’s performance in the last year - US Post News
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St
**Seres Therapeutics, Inc. Posts Updated Corporate Presentation – 8-K Filing Review**** - Defense World
Seres Therapeutics receives $50 million from Nestlé Health Science By Investing.com - Investing.com Australia
Seres Therapeutics receives $50 million from Nestlé Health Science - MSN
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale - The Manila Times
Seres Therapeutics Receives $50M Payment from Nestlé, Extends Cash Runway to 2026 - StockTitan
Seres Therapeutics Strengthens Future with VOWST Sale - TipRanks
Seres Therapeutics Provides Corporate Updates and Financial Results - Defense World
Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell” - Defense World
StockNews.com Downgrades Seres Therapeutics (NASDAQ:MCRB) to Sell - MarketBeat
Seres announces new translational biomarker results from SER-155 Phase 1b study - Yahoo Finance
Geode Capital Management LLC Acquires 255,014 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates - The Manila Times
Seres Therapeutics Announces New Translational Biomarker - GlobeNewswire
Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows - StockTitan
State Street Corp Purchases 43,700 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - Defense World
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageTime to Sell? - MarketBeat
5 Best Microbiome Companies (January 2025) - Securities.io
The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable - Yahoo Finance
Charles Schwab Investment Management Inc. Has $708,000 Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference - Yahoo Finance
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - citybiz
Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference - The Manila Times
Seres Therapeutics' Breakthrough Therapy Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders - The Eastern Progress Online
Seres’ SER-155 gains breakthrough status for BSIs reduction - Yahoo Finance
MCRBSeres Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) - The Manila Times
FDA Grants Breakthrough Therapy Designation to Seres - GlobeNewswire
Seres' SER-155 Wins FDA Breakthrough Status After Stunning 77% Infection Reduction in Transplant Study - StockTitan
Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times
Seres Therapeutics CEO to Present at Piper Sandler Healthcare Conference | MCRB Stock News - StockTitan
Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 By Investing.com - Investing.com Nigeria
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.82%
0.53%
자본화:
|
볼륨(24시간):